Guidelines of care for the management of atopic dermatitis

Section 4. Prevention of disease flares and use of adjunctive therapies and approaches

Work Group: Robert Sidbury, MD (Co-chair), Wynnis L. Tom, MD, James N. Bergman, MD, Kevin D. Cooper, MD, Robert A. Silverman, MD, Timothy G. Berger, MD, Sarah L. Chamlin, MD, MSCI, David E. Cohen, MD, Kelly M. Cordoro, MD, Dawn M. Davis, MD, Steven R. Feldman, MD, PhD, Jon M. Hanifin, MD, Alfons Krol, MD, David J. Margolis, MD, PhD, Amy S. Paller, MD, Kathryn Schwarzenberger, MD, Eric L. Simpson, MD, Hywel C. Williams, DSc, Craig A. Elmets, MD, Julie Block, BA, Christopher G. Harrod, MS, Wendy Smith Begolka, MBS, and Lawrence F. Eichenfield, MD (Co-chair)

Seattle, Washington; San Diego, San Francisco, and San Rafael, California; Vancouver, British Columbia, Canada; Cleveland, Ohio; Fairfax, Virginia; Chicago and Schaumburg, Illinois; New York, New York; Rochester, Minnesota; Winston-Salem, North Carolina; Portland, Oregon; Philadelphia, Pennsylvania; Memphis, Tennessee; Nottingham, United Kingdom; and Birmingham, Alabama

Atopic dermatitis is a common, chronic inflammatory dermatosis that can affect all age groups. This evidence-based guideline addresses important clinical questions that arise in its management. In this final section, treatments for flare prevention and adjunctive and complementary therapies and approaches are reviewed. Suggestions on use are given based on available evidence. (J Am Acad Dermatol http://dx.doi.org/10.1016/j.jaad.2014.08.038.)

Key words: aeroallergens; allergy testing; atopic dermatitis; calcineurin inhibitors; complementary therapy; corticosteroids; diet; education; flare; food allergy; topicals.

DISCLAIMER

Adherence to these guidelines will not ensure successful treatment in every situation. Furthermore, these guidelines should not be interpreted as setting a standard of care or be deemed inclusive of all proper methods of care nor exclusive of other methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding the propriety of any specific therapy must be made by the physician and the patient in light of all the circumstances presented by the individual patient, and the known variability and biologic behavior of the disease. This guideline reflects the best available data at the time the guideline was prepared. The results of future studies may require revisions to the recommendations in this guideline to reflect new data.

From the Department of Dermatology, Seattle Children’s Hospital; University of California, San Diego and Division of Pediatric and Adolescent Dermatology, Rady Children’s Hospital, San Diego; Department of Dermatology and Skin Science, University of British Columbia, Vancouver; Department of Dermatology, Case Western University; private practice, Fairfax; Department of Dermatology, University of California San Francisco; Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago; Department of Dermatology, New York University School of Medicine; Department of Dermatology, Mayo Clinic, Rochester; Department of Dermatology, Wake Forest University Health Sciences, Winston-Salem; Department of Dermatology, Oregon Health & Science University, Portland; Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia; Kaplan-Ammonette Department of Dermatology, University of Tennessee Health Science Center, Memphis; Centre of Evidence-Based Dermatology, Nottingham University Hospitals National Health Service Trust, Nottingham; Department of Dermatology, University of Alabama at Birmingham; National Eczema Association, San Rafael; and the American Academy of Dermatology, Schaumburg.

Funding sources: None.

The management of conflict of interest for this guideline series complies with the Council of Medical Specialty Societies’ Code of Interactions with Companies. The authors’ conflict of interest/disclosure statements appear at the end of this article.

Accepted for publication August 22, 2014.
Reprint requests: Wendy Smith Begolka, MBS, American Academy of Dermatology, 930 E Woodfield Rd, Schaumburg, IL 60173.
E-mail: wsmithbegolka@aad.org.
Published online September 25, 2014. 0190-9622/$36.00 © 2014 by the American Academy of Dermatology, Inc.
Abbreviations used:
AAD: American Academy of Dermatology
ACD: allergic contact dermatitis
AD: atopic dermatitis
APT: atopy patch tests
HDM: house dust mite
IgE: immunoglobulin E
ICD: irritant contact dermatitis
NIAID: National Institute of Allergy and Infectious Disease
SCORAD: SCORing Atopic Dermatitis
SPT: skin prick tests
TCI: topical calcineurin inhibitors
TCM: traditional Chinese medicine
TCS: topical corticosteroids
RCT: randomized controlled trial

SCOPE
This guideline addresses the treatment of pediatric and adult atopic dermatitis (AD; atopic eczema) of all severities. The treatment of other forms of eczematous dermatitis is outside the scope of this document. Recommendations on AD management are subdivided into 4 sections given the significant breadth of the topic, and to update and expand on the clinical information and recommendations previously published in 2004. This document is the final in the series of 4 publications and discusses the management and control of AD flares using topical modalities and the utility and timing of allergen testing and avoidance. Also discussed is the use of adjunctive therapies and approaches, such as environmental, dietary, and educational interventions, in addition to complementary therapies.

METHOD
A work group of recognized AD experts was convened to determine the audience and scope of the guideline and to identify important clinical questions in the management of flare progression and the use of adjunctive therapies and approaches (Table 1). Work group members completed a disclosure of interests that was updated and reviewed for potential relevant conflicts of interest throughout guideline development. If a potential conflict was noted, the work group member recused him or herself from discussion and drafting of recommendations pertinent to the topic area of the disclosed interest.

An evidence-based model was used, and evidence was obtained using a search of the PubMed and the Global Resources for Eczema Trials databases from November 2003 through November 2012 for clinical questions addressed in the previous version of this guideline published in 2004, and from 1960 to 2012 for all newly identified clinical questions determined by the work group to be of importance to clinical care. Searches were prospectively limited to publications in the English language. Medical Subject Headings terms used in various combinations in the literature search included: atopic dermatitis, atopic eczema, surveillance, long-term management, short-term management, short-term care, long-term care, flare progression, relapse, patient follow-up, patient compliance, contact allergen, contact allergy screen, contact allergy test, desensitization, allergen antibody, anti-allergen, antibody, dust mites, environmental, food allergy, irritant avoidance, detergent, clothing, diet, supplement, food introduction, oil, pyridoxine, vitamin, zinc, education, complementary, alternative, herb, supplement, homeopathy, massage, acupuncture, and Chinese medicine.

A total of 2062 abstracts were initially assessed for possible inclusion. After the removal of duplicate data, 287 were retained for final review based on relevancy and the highest level of available evidence for the outlined clinical questions. Evidence tables were generated for these studies and used by the work group in developing recommendations. The Academy’s previously published guidelines on AD were evaluated, as were other current published guidelines on AD.2-5

The available evidence was evaluated using a unified system called the Strength of Recommendation Taxonomy (SORT) developed by editors of the US family medicine and primary care journals (ie, American Family Physician, Family Medicine, Journal of Family Practice, and BMj USA).6 Evidence was graded using a 3-point scale based on the quality of methodology (eg, randomized control trial, case control, prospective/retrospective cohort, case series, etc) and the overall focus of the study (ie, diagnosis, treatment/prevention/screening, or prognosis) as follows:

I. Good-quality patient-oriented evidence (ie, evidence measuring outcomes that matter to patients: morbidity, mortality, symptom improvement, cost reduction, and quality of life).

II. Limited-quality patient-oriented evidence.

III. Other evidence, including consensus guidelines, opinion, case studies, or disease-oriented evidence (ie, evidence measuring intermediate, physiologic, or surrogate end points that may or may not reflect improvements in patient outcomes).

Clinical recommendations were developed based on the best available evidence tabbed in the guideline. These are ranked as follows:

A. Recommendation based on consistent and good-quality patient-oriented evidence.
B. Recommendation based on inconsistent or limited-quality patient-oriented evidence.
C. Recommendation based on consensus, opinion, case studies, or disease-oriented evidence.

In those situations where documented evidence-based data are not available, we have used expert opinion to generate our clinical recommendations.

This guideline has been developed in accordance with the American Academy of Dermatology (AAD)/AAD Association Administrative Regulations for Evidence-based Clinical Practice Guidelines (version approved May 2010), which includes the opportunity for review and comment by the entire AAD membership and final review and approval by the AAD Board of Directors. This guideline will be considered current for a period of 5 years from the date of publication, unless reaffirmed, updated, or retired at or before that time.

**DEFINITION**

AD is a chronic, pruritic inflammatory skin disease that occurs most frequently in children, but also affects many adults. It follows a relapsing course. AD is often associated with elevated serum immunoglobulin (IgE) levels and a personal or family history of type I allergies, allergic rhinitis, and asthma. Atopic eczema is synonymous with AD.

**INTRODUCTION**

The often protracted nature of AD necessitates setting several long-term treatment goals: the prevention of continued outbreaks, the management of comorbidities and secondary complications that arise, and minimizing adverse effects while trying to maximize positive outcomes. Clinical studies focused on more extended disease control have increased in recent years. Additional data regarding allergic comorbidities support the need for testing or intervention, but only in particular instances. In addition to the topical and systemic approaches reviewed in earlier parts of these guidelines, multiple adjunctive and complementary modalities have been tried, with varying degrees of success. Discussion of these measures and suggestions on their use are provided based on the available evidence.

**PREVENTION OF DISEASE FLARES**

AD is characterized by periods of acute worsening (“flares”) alternating with periods of relative quiescence after treatment. The precise definition of a flare, however, differs across studies and is an ongoing area of research. For pragmatic reasons, the definitions of flare from each published paper have been accepted for this guideline.

The strategy required to minimize recurrence varies depending on the individual and his or her frequency, severity, and sites of disease. Moisturizers should be an integral part of the maintenance treatment plan given their low risk and ability to improve skin hydration; some may also address the negative effects of epidermal barrier dysfunction. Two studies have shown that daily moisturizer use can lengthen the time to first flare, compared to no treatment. In some cases, this strategy may be adequate and antiinflammatory therapies reinstituted only when new eczematous lesions are noted. This is considered a reactive approach to long-term management.

However, some individuals benefit from a more proactive method, whereby topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) are applied to both previously and newly involved skin on a scheduled, intermittent basis and moisturizers used on all areas. Five randomized controlled trials (RCTs) with up to 4 weeks of acute disease control followed by twice weekly application of a midpotency TCS (fluticasone propionate or methylprednisolone aceponate) for 16 to 20 weeks demonstrated a reduction in the risk of flare development and lengthening of the time to relapse or first flare, relative to vehicle. A metaanalysis of the fluticasone studies found a substantial magnitude of benefit (pooled relative risk of flares of 0.46 [95% confidence interval [CI], 0.38-0.55] vs vehicle). Two to 3 times weekly application of topical tacrolimus (0.03% in children, 0.1% in adults) to previously affected sites revealed similar benefits over 40 to 52 weeks of use (3 RCTs, pooled relative risk of flares of 0.78 [95% CI, 0.60-1.00]). This method of TCI use also led to a decrease in the number of flares and an increase in days free of topical antiinflammatory use compared to vehicle.

The recommendation for flare prevention is in Table II and level of evidence in Table III. Further supporting proactive treatment are histologic findings of a persistently abnormal epidermal barrier and residual low-grade inflammation at previously involved sites, even when there is little clinical evidence of involvement.

The proactive application of TCS or TCIs appears to be an effective strategy for AD flare prevention, but there remain unanswered questions with use. Because there are no studies directly comparing the 2 classes of topical therapy used in this manner, it is not clear if 1 intervention is more effective, although a metaanalysis of the vehicle-controlled trials suggested that topical fluticasone is superior to tacrolimus in preventing relapses. Skin atrophy was not noted with scheduled, intermittent TCS use,
Table I. Clinical questions used to structure the evidence review for the management and treatment of atopic dermatitis with topical therapies

- What are the most effective approaches to preventing flares in patients with atopic dermatitis?
- What types of educational interventions are used in patients with atopic dermatitis to improve patient outcome, and are they effective?
- What is the utility of screening for allergens on the course of atopic dermatitis and what are the suggested testing methods?
- What is the effectiveness of dietary interventions, such as dietary restriction based on food allergy and sensitization testing, and the use of supplements, such as evening primrose oil, borage oil, fish oil, pyridoxine, vitamin E, multivitamins, and zinc for the treatment of atopic dermatitis?
- What environmental modifications, such as house dust mite reduction, choice of clothing, irritant avoidance, and use of detergents can be implemented to influence the course of atopic dermatitis?
- What is the effect of allergen-based interventions (eg, desensitization injections, allergen—antibody complexes of house dust mites) on the course of atopic dermatitis?
- What is the effectiveness of complementary therapies, such as Chinese herbs and other supplements, homeopathy, and massage therapy for the treatment of atopic dermatitis?

Table II. Recommendation for prevention of flares of atopic dermatitis

| Continued use of either topical corticosteroids (1-2 times/wk) or topical calcineurin inhibitors (2-3 times/wk) after disease stabilization, to previously involved skin, is recommended to reduce subsequent flares or relapses. |

Although 1 study recorded a higher rate of viral and respiratory tract infections and another found increased ear, nose, and throat symptoms.14,16-19 Two TCS studies did not observe adrenal suppression after the 16-week maintenance period, while a third long-term safety study of up to 44 weeks of intermittent treatment noted abnormal cosynotropin stimulation testing in 2 of 44 subjects.14,17,19 The risk-benefit ratio of proactive TCS use beyond 44 weeks has not been tested, and the need for transition to TCI or other strategies is unclear. Side effects for proactive TCI use were mainly application site reactions, and in one study skin infections and nasopharyngitis occurred, but these side effects were also seen with the vehicle.21-23

The continued daily use of TCI also reduced the risk of flare in long-term studies to 12 months,25,26 but efficacy compared to scheduled, intermittent dosing is unknown. Given the current black box warning against continuous TCI use (see Section 2), it seems prudent to apply them intermittently to minimize any potential long-term risks.

The optimal interval of scheduled intermittent use is not clear because of the variation between studies in terms of twice weekly, 3 times weekly, and 2 consecutive days weekly of application. Additional variation stems from some studies applying the topical antiinflammatory once daily and others twice daily.

Methods to identify best candidates for a proactive approach would be helpful. Some studies focused on those with moderate to severe disease based on severity scores, but many scales do not distinguish patients with very intermittent flares over a moderate or more extensive amount of body surface area from those with persistent disease at the same body sites compared to patients with rapid disease recurrence on TCS or TCI discontinuation. Skin type may also affect flare identification, and there may be a need for different definitions or approaches to account for these factors.

EDUCATIONAL INTERVENTIONS

The education of patients and caregivers is itself an important form of intervention (recommendations in Table IV, level of evidence in Table III). Because AD has a complex pathogenesis and involves multiple (and sometimes rotating) therapies, it inherently requires much teaching and support to achieve and maintain good response. Increased knowledge of disease mechanisms and course, the appropriate use of therapies, and the goals of management can improve treatment adherence and lessen fears and misconceptions.27 Educational methods vary greatly in scope, intensity, frequency, setting, and personnel used. Disease-directed teaching can be on an individual or group basis.

Formal, structured multidisciplinary educational programs (ie, training programs or “eczema schools”) for children and adults have already been established in some countries.28-31 The largest RCT to date involved 823 German children and adolescents with moderate to severe AD and their families. A 6-week educational program consisting of once-weekly, 2-hour sessions led by a team
having dermatologic, nutritional, and psychological components resulted in decreased disease severity as measured by the SCORing Atopic Dermatitis (SCORAD) index, relative to the control group.30 There have also been significant improvements in subjective assessments of severity, itching behavior, and ability to cope in groups receiving structured education.30,32,33 Increased adaptive use of medication based on AD severity has also been shown.33 Such formal training programs have the strongest supportive evidence but do require significant personnel and financial resources. Comparison between programs is difficult because the content is heterogeneous and outcome measures vary greatly between studies.34

Because physician time during clinic visits is often limited, workshops and nurse-led educational sessions can be of benefit to patients, improving the knowledge and use of topical treatments.35-41 One systematic review found increased patient satisfaction as a result of longer consultation and similar health outcomes to doctor-led care.37 Other educational methods include parental education via standardized video instruction, which in one RCT was more effective than direct parental teaching in improving AD symptoms, and in a second RCT, led to greater improvements in severity score and AD knowledge than a written pamphlet.41,42 In addition, video-assisted approaches were less time consuming.41

Written action plans also assist in reinforcing teachings.43 Practitioners should be aware of educator and lay-led management resources, such as the educational information and support groups provided by organizations such as the National Eczema Association (http://nationaleczema.org/). These facilitate communication and networking between affected patients and families, although

### Table III. Strength of recommendations for the use of topical therapies for flare prevention and for adjunctive and complementary interventions for the treatment of atopic dermatitis

<table>
<thead>
<tr>
<th>Therapy/intervention</th>
<th>Strength of recommendation</th>
<th>Level of evidence</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proactive use of topical corticosteroids</td>
<td>A</td>
<td>I</td>
<td>14,16-20</td>
</tr>
<tr>
<td>Proactive use of topical calcineurin inhibitors</td>
<td>A</td>
<td>I</td>
<td>21-23</td>
</tr>
<tr>
<td>Structured education programs</td>
<td>A</td>
<td>I</td>
<td>28-33</td>
</tr>
<tr>
<td>Video interventions</td>
<td>B</td>
<td>II</td>
<td>41,42</td>
</tr>
<tr>
<td>Eczema workshops, nurse-led programs</td>
<td>B</td>
<td>II</td>
<td>35-40</td>
</tr>
<tr>
<td>Elicit history of environmental and food allergies</td>
<td>B</td>
<td>II</td>
<td>46-48,151</td>
</tr>
<tr>
<td>Allergy assessment if positive history elicited</td>
<td>B</td>
<td>II</td>
<td>46,51,52,56,65,71,151,152</td>
</tr>
<tr>
<td>Patch testing for ACD</td>
<td>B</td>
<td>II</td>
<td>73-75,83,84</td>
</tr>
<tr>
<td>Against food elimination based on allergy tests only</td>
<td>B</td>
<td>II</td>
<td>87,153-157</td>
</tr>
<tr>
<td>Avoidance if true IgE-mediated allergy</td>
<td>A</td>
<td>I</td>
<td>46,90</td>
</tr>
<tr>
<td>Against routine use of probiotics/prebiotics for treatment of established AD</td>
<td>B</td>
<td>II</td>
<td>94-98</td>
</tr>
<tr>
<td>Insufficient evidence to recommend fish oils, evening primrose oil, borage oil, multivitamin supplements, zinc, vitamin D, vitamin E, and vitamins B₁₂ and B₆</td>
<td>B</td>
<td>II</td>
<td>99-114</td>
</tr>
<tr>
<td>Against routine use of house dust mite covers</td>
<td>B</td>
<td>II</td>
<td>115-119</td>
</tr>
<tr>
<td>Against specific laundering techniques or specific products</td>
<td>C</td>
<td>III</td>
<td>120,121</td>
</tr>
<tr>
<td>Insufficient evidence to recommend specialized clothing fabrics</td>
<td>B</td>
<td>II</td>
<td>128-130</td>
</tr>
<tr>
<td>Against sublingual and injectional immunotherapy for the general AD population</td>
<td>B</td>
<td>II</td>
<td>132-140</td>
</tr>
<tr>
<td>Insufficient evidence to recommend Chinese herbal therapy</td>
<td>C</td>
<td>III</td>
<td>141-143</td>
</tr>
<tr>
<td>Insufficient evidence to recommend massage therapy</td>
<td>B</td>
<td>II</td>
<td>146,147</td>
</tr>
<tr>
<td>Insufficient evidence to recommend aromatherapy, naturopathy, hypnotherapy, acupressure, or autologous blood injections</td>
<td>B</td>
<td>II and III</td>
<td>148,149</td>
</tr>
</tbody>
</table>

ACD, Allergic contact dermatitis; AD, atopic dermatitis; IgE, immunoglobulin E.

### Table IV. Recommendations for educational interventions for atopic dermatitis

Educational programs (ie, training programs and “eczema schools”) are recommended as an adjunct to the conventional therapy of atopic dermatitis.

Video interventions can be recommended as an adjunct to conventional therapy.

Eczema workshops and nurse-led programs may be useful as an adjunct to conventional therapy.
their effects on AD outcomes have not been formally tested.

Psychological interventions have also been used to help with coping with AD, and include autogenic training, biofeedback, brief dynamic psychotherapy, cognitive behavioral therapy, habit reversal behavioral therapy, and a stress management program. Most of these adjunctive therapies are limited to case series that use different outcome measures that preclude comparison.44 One RCT of children receiving hypnotherapy or biofeedback had a statistically significant reduction in the severity of surface damage and lichenification, but not in erythema, compared to the control group.54

COEXISTING ALLERGIC DISEASE AND ALLERGY TESTING

Patients and caregivers often seek allergy assessment to find a single cause or trigger that could be eliminated to obtain “cure”—or at least reduce the need for treatment. However, the role of allergens in eliciting and maintaining AD skin lesions is complex, further complicated by challenges in determining clinical relevance and their importance relative to other factors. Foods and inhalant/aeroallergens are common concerns, and along with contact allergens are the most relevant for discussion.

Food allergies

A fair number of children and a much smaller percentage of adult patients with AD have food allergies, particularly those of younger age and with more severe disease.45 The exact impact of food exposure on the course of AD remains unclear. Asthma is a stronger risk factor for food allergy than AD.

A true allergy is defined as “an adverse health event that results from stimulation of a specific immune response that occurs reproducibly on exposure.”46 Therefore, reproducible clinical symptoms or signs after food exposure/ingestion are necessary to diagnose food allergy, and broad panel allergy testing independent of a history of a delayed disease in spite of optimized management and topical therapy; (2) a reliable history of an immediate allergic reaction after ingestion of a specific food; or (3) both.46 While food allergy is less common in older age groups, when suspected, the choice of food for testing should be made according to the clinical history and to the most prevalent allergies in a given population. Tree nuts, shellfish, and fish become relevant in subsequent childhood years.48 In older children, adolescents, and adults, pollen-related food allergy should be taken into account—for example, those with birch pollen allergy may developing itching in their mouth with exposure to apples, celery, carrots, and hazelnuts.49

Tests often performed for evaluation include skin prick testing (SPT) and serum-specific IgE level determination, which assess for immediate/type I hypersensitivity reactions. SPT is an in vivo test based on introducing allergen extracts that bind to specific IgE antibodies on mast cells, causing the release of histamine and other mediators that give rapid formation of a wheal and flare. Food-specific IgE levels may be measured in the serum by in vitro assays, such as radioallergosorbent (RAST) testing or immunoCAP testing. In cases of extensive eczematous lesions, prominent dermatographism, or the recent use of oral antihistamines, specific IgE measurement may be preferable over SPT. With both tests, the negative predictive value is high (>95%) and the specificity and positive predictive value are low (40-60%).50-52 Negative test results are helpful to rule out food allergy, but positive results only signify sensitization and require clinical correlation and confirmation to establish presence of allergic disease and the exact type of allergic response. Higher specific IgE levels and larger wheal sizes (>8-10 mm) are associated with a greater likelihood of reaction on challenge.46 Measuring total serum IgE levels alone, or to compare with allergen-specific levels, is not helpful in determining food allergy.46,53
In recent years, atopy patch tests (APT) have been introduced to assess for type IV hypersensitivity/eczematous reactions. These involve applying custom-made food material for 48 to 72 hours to the back using 8- to 12-mm test chambers. Food APT are not commonly used in the evaluation of patients in North America, but have been investigated in Europe. One European multicenter study found that APTs have a higher specificity than SPTs or specific IgE, particularly in the case of wheat, while other studies noted that APT could not predict food hypersensitivity beyond that of SPT or specific IgE testing. These conflicting findings might be explained by the sometimes difficult interpretation of APT because of nonspecific reactions. In addition, while AD patients have more reactivity than healthy controls, the results do not necessarily correlate with disease severity or clinical outcome, and APT are therefore not recommended for routine use at this time.

Positive skin or blood tests ideally need to be verified by controlled food challenges. The criterion standard for diagnosing food allergy is a double-blind, placebo-controlled oral food challenge. In this case, testing is performed after a washout period. Potential allergenic foods and placebo are given in a randomized, titrated fashion, and both the patient and observer are blinded to the test food. Because this may not always be practical, open-label or single-blind oral food challenges are more commonly used in clinical practice to screen for reactions. Such challenges should be performed under the guidance of well-trained medical personnel and with emergency equipment available. Another alternative is careful assessment of the effects of a food elimination diet carried out in the absence of other exacerbating factors. Avoidance diets should be cautiously undertaken, however, and are further discussed below (see Dietary Interventions).

Even if food allergies are present, effective treatment for AD is still centered on good skin care and topical therapies. In addition, children with clinically significant food allergy will often develop tolerance over time to milk, egg, soy, and wheat, and therefore these allergens can be retested with age. Food allergies in adults can reflect persistence of childhood allergies or de novo sensitization to allergens encountered after childhood. Although data are limited, there is a suggestion that food allergies starting in adult life tend to be persistent.

Inhalant/aeroallergens

In contrast to food allergy, reactivity to aeroallergens increases with age. Common aeroallergens include house dust mites, pollens, animal dander, and fungi, and higher rates of sensitization are noted in those with moderate to severe AD. As with foods, true allergy to aeroallergens requires demonstration of an adverse health event that is reproducible on exposure, along with discernment of the clinical reaction. The exact role of aeroallergens in AD pathogenesis is controversial, because inhalation may induce the release of proinflammatory cytokines in the skin of sensitized patients, but avoidance measures have not consistently helped (discussed under Environmental Modifications). Skin contact with aeroallergens triggers eczematous skin lesions in some individuals but not others (5-45% positivity, depending on the allergen).

The diagnosis of allergy to an aeroallergen is based on a sequential workup and demonstration of clinical relevance. History can be helpful to identify pollens or animal dander as potential triggers, such as seasonal flares or exacerbation of AD lesions after contact. Aeroallergens may also be suspected if the dermatitis is more severe on exposed surfaces of the face, neck, arms, legs, and “V” area of the chest. In a second step, SPT or measurement of specific IgE antibodies can be performed to detect sensitization.

APTs with epicutaneous application of aeroallergens on uninvolved atopic skin has also been used for testing. Positive eczematoid reactions have been observed in 30% to 50% of patients with AD, but only rarely in patients with respiratory allergy or healthy volunteers. Some noted APT to have a higher specificity but lower sensitivity than SPT or specific IgE for potential aeroallergen triggers, while Kerschenlohr et al reported positive APT in patients with AD even in the absence of detectable aeroallergen-specific serum IgE and with negative SPT results. Some have suggested APT use when there is a high suspicion of aeroallergen-related symptoms or if there is severe and/or persistent AD with unknown triggering factors. The major disadvantage with APT, however, is the variability of methods and interpretation of results among investigators, along with the lack of a commercially available product. Standardization of the procedure has been proposed, but is hampered by the lack of a comparator gold standard test that establishes the diagnosis of aeroallergen-induced or exacerbated dermatitis.

Allergic contact dermatitis

The high prevalence of allergic contact dermatitis (ACD) has been increasingly recognized in individuals with AD. ACD is a type IV/delayed
The most common contact allergens in patients with AD include nickel, neomycin, fragrance, formaldehyde and other preservatives, lanolin, and rubber chemicals. A small subset of patients may even develop ACD to some TCS and can pose a diagnostic dilemma for the clinician. A diagnosis of ACD is made by patch testing, whereby suspected allergens are placed on unaffected skin, typically the back, for 48 hours. Presence of a reaction should be assessed at the time of initial patch removal and again at a later time point, up to 7 days after application, for delayed reactions. Patch testing should be considered in cases where a history and/or physical examination is suggestive of ACD, such as disease aggravated by topical medications or emollients or patterns that reflect application of, or exposure to, a consistent item, such as marked facial and/or eyelid involvement, increased severity at the flexures of the neck, and vesicular lesions on the dorsal surfaces of the hands and fingertips (recommendation in Table V, level of evidence in Table III). Testing may also be considered where there is an unusual and atypical distribution of lesions for AD (eg, on the sides of the feet), if there is later onset of disease or new significant worsening, if there is no family history of atopy, and in patients with persistent/recalcitrant disease that has not responded to standard AD therapies. Even some cases of generalized dermatitis may involve ACD, such as to fragrances, preservatives, cleansers, and textiles, but are a challenge to recognize and to test for if there is little uninvolved skin. The sensitivity of patch testing ranges from 60% to 80%. Positive patch tests only indicate contact sensitization and need demonstrated relevance to the patient’s active dermatitis and sometimes confirmation by repeat open application testing of products containing the allergen that have been in contact with the patient. Avoidance of the suspected allergen with resolution of the corresponding dermatitis confirms the diagnosis of ACD.

### Table V. Recommendations for testing for coexisting allergic disease

<table>
<thead>
<tr>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atopic dermatitis patients have an increased rate of environmental and food allergies, and physicians should assess for these conditions during history taking. If significant concerns for allergy are identified (ie, hives, urticaria, etc) assessment can be undertaken. Allergy testing independent of history is not recommended.</td>
</tr>
<tr>
<td>Patch testing should be considered in patients with atopic dermatitis who have persistent/recalcitrant disease and/or a history or physical examination findings consistent with allergic contact dermatitis.</td>
</tr>
</tbody>
</table>

In summary, allergens may be pertinent to some AD patients but require a detailed history, careful evaluation, and correlation of allergy test results to determine clinical relevance. It is extremely rare to find 1 allergen responsible for AD, which is a complex multifactorial disease in which nonallergic factors, such as climate and secondary infection, may also be implicated.

### DIETARY INTERVENTIONS

#### Food elimination/avoidance diets

Large numbers of patients with AD, particularly children, are started on empiric food elimination/avoidance diets. However, there is a frequent misattribution of AD flares to food-related issues. Food allergies may coexist and represent important triggers in a small subset of individuals with AD (usually those with moderate to severe disease), but the true frequency of food allergies causing an isolated flare of disease is probably low.

Elimination diets should not be initiated based on presence of AD or a suspicious history alone. A 2008 Cochrane review concluded that there may be some benefit to an egg-free diet in infants with suspected egg allergy who also have positive specific IgE to eggs, but other exclusion diets (eg, milk-free, elemental, few-foods diets) were not found to be efficacious in unselected AD populations. If allergy is suspected as a trigger of AD, a food diary recording symptoms and intake can be helpful in identifying a specific food. If there is consistent correlation of symptoms (with or without positive allergy testing), a diagnostic elimination diet for up to 4 to 6 weeks with the suspected food item(s) may be initiated. If the individual’s AD remains stable or even increases in severity, it is unlikely that the food is a relevant AD trigger and additional testing is not necessary. If there is an improvement of the symptoms during a diagnostic elimination diet, an oral food challenge should be performed under the guidance of an
allergist, because the skin improvement may be coincidental or reflect a placebo effect.56,88 If a patient has positive allergy tests but no history of symptomatic food allergy, review with an allergist regarding the issue of true versus false positive tests (allergy vs only sensitization) is warranted, along with discussion of benefits and downsides of formal food challenge. A retrospective study by Fleischer et al90 on the outcome of oral food challenges in children with AD after elimination diets primarily based on sensitization found that 84% to 93% of the avoided foods could be returned to the diet and could be tolerated.

Multiple dietary restrictions and long-term dietary avoidance should only be undertaken with documented, clinically relevant food allergies.46 Excessively restrictive diets, especially in atopic children, have led to weight loss, poor growth, calcium deficiency, hypovitaminosis, and kwashiorkor.91,92 Proper medical supervision, nutritional counseling from a dietician, and supplementation should be included if elimination/avoidance diets are pursued for any prolonged period of time. Even in those individuals with clinically relevant food allergy, avoidance diets are generally helpful to avoid the effects of IgE-mediated/immediate reactions but are unlikely to affect the course of AD.56,87 A summary of these recommendations is shown in Table VI, with the level of evidence in Table III.

**Probiotics/prebiotics**

The study of probiotics for AD management stems from the finding that the intestinal microbiota is different in those with and without AD.93 Probiotics are live microorganisms that modify the overall composition of this microbiota and potentially modulate the host immune response. However, studies have found limited evidence to support their use as a treatment for established AD.94 A Cochrane review of 12 RCTs involving 785 children (age 3 months to 13 years) included a variety of probiotic strains and found no significant differences in symptoms or disease severity compared to placebo.95 On metaanalysis, the effect of probiotics, even if present, was small and likely not clinically noticeable (a statistically significant SCORAD decrease of 2.47 points [95% CI, −4.72 to −0.21]; P = .03; noted only after correcting for baseline severity differences; 2 studies could not be pooled with this method). Three studies included prebiotics, specialized plant fibers to help nourish the bacteria, but also with mixed effects.96-98 Pro-/prebiotic use cannot be recommended at this time (level of evidence in Table III).

**Table VI. Recommendations for other adjunctive and complementary interventions for the treatment of atopic dermatitis**

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Level of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Food elimination diets based solely on the findings of food allergy test results are not recommended for the management of AD.</td>
<td>I</td>
</tr>
<tr>
<td>If a patient has a true immunoglobulin E—mediated allergy, he or she should practice avoidance to prevent potential serious health sequelae.</td>
<td>I</td>
</tr>
<tr>
<td>Children &lt;5 years of age with moderate to severe AD should be considered for food allergy evaluation for milk, egg, peanut, wheat, and soy if at least 1 of the following is met: (A) persistent AD in spite of optimized treatment or (B) having a reliable history of immediate reaction after ingestion of a specific food.</td>
<td>II</td>
</tr>
<tr>
<td>The use of probiotics/prebiotics for the treatment of patients with established AD is not recommended because of inconsistent evidence.</td>
<td>II</td>
</tr>
<tr>
<td>There is inconsistent to no evidence to recommend the use of fish oils, evening primrose oil, borage oil, multivitamin supplements, zinc, vitamin D, vitamin E, and vitamins B₁₂ and B₆ for the treatment of AD.</td>
<td>II</td>
</tr>
<tr>
<td>There is limited evidence to support the routine use of house dust mite covers to treat patients with AD who are sensitized to dust mites.</td>
<td>III</td>
</tr>
<tr>
<td>The use of specific laundering techniques, such as double rinsing, detergents, or other laundry products cannot be recommended for AD treatment because of the lack of clinical studies.</td>
<td>III</td>
</tr>
<tr>
<td>There is limited evidence to support the use of specialized clothing fabrics in the treatment of AD.</td>
<td>III</td>
</tr>
<tr>
<td>In the general AD population, sublingual immunotherapy and injection immunotherapy are not recommended for the treatment of AD because of the small number of studies and conflicting conclusions.</td>
<td>III</td>
</tr>
<tr>
<td>Chinese herbal therapy and massage therapy have insufficient evidence for recommendation for AD treatment.</td>
<td>III</td>
</tr>
<tr>
<td>The use of aromatherapy, naturopathy, hypnotherapy, acupressure, or autologous blood injections cannot be recommended for the treatment of AD at this time because of insufficient evidence.</td>
<td>III</td>
</tr>
</tbody>
</table>

AD, Atopic dermatitis.
Other dietary supplements

A deficiency of essential fatty acids in the skin has been proposed as having a role in AD. Fish oils are particularly rich in n-3 fatty acids, and are suggested to compete with n-6 fatty acids in a manner that reduces the inflammatory components of AD. There is, however, little supportive data for either.99-101 Evening primrose oil and borage oil have been tried orally because of their gamma-linolenic acid content, and these oils are considered to have antiinflammatory properties. Several RCTs of evening primrose oil have had mixed results, with the majority of data finding no benefit.102-106 Two RCTs evaluating the use of oral borage oil in the treatment of AD did not show improvement in key outcomes compared with placebo.107,108

Vitamins and minerals have also been tried, but none with adequate data to support their use.109 Multivitamins have not been tested alone; zinc was not helpful in 1 RCT.110 Some studies suggest a mild positive effect for vitamin D and E supplementation, but larger, well-controlled trials are warranted before any formal recommendations can be made.111-113 Topical B12 cream was helpful in one 4-week blinded study but has not been tested further. Vitamin B6/pyridoxine supplementation did not make any difference in one 4-week, placebo-controlled study.114

ENVIRONMENTAL MODIFICATIONS

Environmental modifications stem from expert/consensus recommendations because there are few well-controlled studies. General recommendations are to avoid known mechanical and chemical irritants, such as wool, acids, bleaches, and solvents, and any clear triggers/exacerbants particular to the individual (eg, excessive heat).

A large majority of studies testing environmental modifications have centered on house dust mite (HDM) interventions. Sensitization to HDM is commonly shown in AD patients, and exposure can also cause a worsening of allergic rhinitis and asthma in sensitized individuals.115 The evidence is limited, however, to support the routine use of HDM avoidance measures. Normal cleaning measures (such as washing bedding weekly and vacuuming frequently) only provide small decreases in HDM allergen present in the room. While covers may reduce levels of HDM and sensitization levels, studies have not shown improvement in AD severity, particularly in adults.115,119 One study did show improvement in children and a greater effect in those most severely affected.116 As a result, the current work group notes that in patients who are sensitized to HDM and whose AD is uncontrolled, the clinician could consider recommending a HDM cover for the pillow and mattress.

There is a paucity of clinical studies on specific laundering techniques (such as double rinsing and other methods), detergents, or other laundry products and their impact on AD management.120,121 The use of ion exchange water softeners for bathing and laundering clothing was not of benefit in a large RCT.122 Products with low pH may be better because of potentially fewer negative effects on the skin barrier, while botanical products (ie, plant-derived extracts and herbs) may not be as they have irritant contact dermatitis and ACD risks.123,124 Fabric softener with perfumes can cause irritation,125,126 but some data indicate that softened fabrics might help because of reduced frictional irritation.127

Smooth clothing and avoidance of irritating fabrics and fibers are favored to minimize skin irritation. There are a small number of controlled studies indicating that specialty silk garments may improve severity scores, although at this time it is not clear whether silk and specialty silks impregnated with antibacterial agents provide significantly more improvement compared to soft cotton.128-130 Clothing impregnated with silver can decrease Staphylococcus aureus density, but did not improve disease severity more than soft cotton in 1 study.131 More research into this area is warranted before recommendations can be offered regarding specialized clothing fabrics, which are associated with higher cost.

OTHER ALLERGEN-BASED INTERVENTIONS

Allergen-specific immunotherapies have been used in the treatment of asthma and allergic rhinitis and are now being tested for AD management. Preliminary studies on sublingual immunotherapy for HDMs yielded modest positive results, which may be more evident in those with milder cases of AD.132,133 Nine to 12 months of immunotherapy were needed to observe the beneficial effect. The present evidence does not warrant routine recommendation of sublingual immunotherapy for HDM-sensitized AD patients. A series of small prospective studies on injection immunotherapy for HDMs also had positive results, although there was also 1 negative study.134-140 Injection immunotherapy for HDM-sensitized patients also cannot be routinely recommended at this time. Studies examining immunotherapy for other aeroallergens are even more limited in number (<5 RCTs), precluding recommendation for use.
COMPLEMENTARY THERAPIES

At this time, there are little data to support the majority of complementary therapies tried for AD management. Chinese herbal therapy (or traditional Chinese medicine [TCM]) has been the most extensively studied. While it may have some benefit for AD lesions, the results from RCTs of TCM taken orally are conflicting, and reports of serious hepatotoxicity raise potential safety concerns. Some herbal creams have been found to be contaminated with TCS. The individualized and dynamic nature of this intervention (eg, a different herb is added or subtracted depending on the patient) also poses challenges to performing controlled studies. Acupuncture alone or in conjunction with TCM decreases signs and symptoms of AD, but the evidence is confined to small studies of limited quality.

Massage therapy may improve symptoms and associated patient and parental anxiety levels. While it is a safe intervention, studies to date are small and of limited quality, precluding recommendation at this time. Other complementary therapies lacking sufficient evidence include: aromatherapy (no studies), homeopathy (1 positive prospective study), naturopathy (no studies), acupressure (1 study), and autologous blood injections (1 study).

GAPS IN RESEARCH

In review of the currently available highest level of evidence, the expert work group acknowledges that while multiple studies have been performed on prevention of flares and the use of adjunctive therapies and approaches, much has yet to be learned. Significant gaps in research were identified, including but not limited to: methodologic research on the best instruments for defining disease flares in long-term AD trials; comparative studies to decide on best agents for long-term maintenance therapy; increased long-term safety data for intermittent use of TCS and TCI; high-quality research on the role of foods and aeroallergens in AD with an emphasis on clear morphologic description of cutaneous reactions; and trials assessing outcomes of ACD testing and avoidance measures in AD patients. Additional large, well-controlled trials are needed to test the effects of adjunctive treatments showing positive data, including vitamins D and E, specialized clothing fabrics, immunotherapy for highly HDM sensitized patients with persistent AD, and complementary therapies.

We thank Melinda Jen, MD, Michael Osofsky, MD, Kathleen Muldowney, MLS, Charmiel McDaniel, MS, and Tammi Matillano for technical assistance in the development of this manuscript. We also thank the AAD Board of Directors, the Council on Science and Research, the Clinical Guidelines Committee, and all commenting Academy members for their thoughtful and excellent comments.

Dr Tom is supported by a National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) research career development grant (K23AR060274). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or NIH.

Disclosure: The below information represents the authors identified relationships with industry that are relevant to the guideline. Relevant relationships requiring recusal for drafting of guideline recommendations and content were not noted for this section. The management of conflict of interest for this guideline complies with the Council of Medical Specialty Societies' Code of Interactions with Companies.

Wynnis L. Tom, MD, served as an investigator for Anacor, receiving no compensation. James N. Bergman, MD, had other relationships with Pedipharma, receiving honoraria, and served as a consultant for Pierre-Fabre, receiving honoraria. Robert A. Silverman, MD, served as a speaker for Galderma and Promius, receiving honoraria. Sarah L. Chamlin, MD, MSCI, served on the advisory boards for Anacor, Galderma, Promius, and Valeant, receiving honoraria. David E. Cohen, MD, served on the advisory boards and as a consultant for Ferndale Labs, Galderma, and Orsent, receiving honoraria; served on the board of directors and as a consultant for Brickell Biotechnology and Topica, receiving honoraria, stock, and stock options; and was a consultant for Dermira and Dr Tatoff, receiving honoraria and stock options. Steven R. Feldman, MD, PhD, served on the advisory boards for Amgen, Doak, Galderma, Pfizer, Pharmaderm, Skin Medica, and Stiefel, receiving honoraria; was a consultant for Abbott, Astellas, Caremark, Coria, Gerson Lehrman, Kikaku, Leo Pharma, Medics, Merck, Merz, Novan, Peplin, and Pfizer, receiving honoraria, and Celgene, HanAll, and Novartis, receiving other financial benefits; was a speaker for Abbott, Amgen, Astellas, Centocor, Dermatology Foundation, Galderma, Leo Pharma, Novartis, Pharmaderm, Sanofi-Aventis, Stiefel, and Taro, receiving honoraria; served as a stockholder and founder for Causa Technologies and Medical Quality Enhancement Corporation, receiving stock; served as an investigator for Abbott, Amgen, Anacor, Astellas, Basilea, Celgene, Centocor, Galderma, Medics, Skin Medica, and Stiefel, receiving grants, and Suncare Research, receiving honoraria; and had other relationships with Informa, UptoDate, and Xlibris, receiving royalty, and Medscape receiving honoraria. Dr Feldman recused himself for the drafting of guideline recommendations related to phototherapy. Jon M. Hanifin, MD, served on the advisory board for Chugai Pharma USA, receiving honoraria; was a consultant for GlaxoSmithKline, Merck, Elocon Advisory Board, Otsuka Pharma, Pfizer, and Valeant Elidel Advisory Board, receiving honoraria; and...
served as an investigator for Asubio and Merck Sharp & Dohme, receiving grants. Alfonso Krol, MD, served as an investigator for Pierre-Fabre, receiving grants. Amy S. Paller, MS, MD, served as a consultant to Anacor, Galderma, Leo Pharma, Promius, Sanofi/Regeneron, and TopMD, receiving honoraria; and was an investigator for Astellas, Galderma, Leo Pharma, and TopMD, receiving no compensation. Eric L. Simpson, MD, served as a consultant for Asubio, Brickell Biotech, Galderma, Medicis, Panmira Pharmaceuticals, and Regeneron, and a speaker for Centocor and Galderma, receiving honoraria; and was an investigator for Amgen, Celgene, Galderma and Regeneron, receiving other financial benefits. Craig A. Elmets, MD, served on a data safety monitoring board for Astellas, receiving honoraria; and was an investigator for Anacor and Bayer, receiving honoraria, and TopMD, receiving stock options; was a consultant and speaker for Galderma, receiving honoraria; served as a consultant, speaker, and member of the advisory board for Medicis/Valeant, receiving honoraria; and was an investigator for Anacor and Astellas, receiving no compensation. Robert Sidbury, MD, Timothy M. Berger, MD, Kevin D. Cooper, MD, Kelly M. Cordoro, MD, Dawn M. Davis, MD, David J. Margolis, MD, PhD, Kathryn Schwarzenberger, MD, Hywel C. Williams, DSc, Julie Block, BA, Christopher G. Harrod, MS, and Wendy Smith Begolka, MBS, have no relevant relationships to disclose.

REFERENCES


